Journavx (Suzetrigine) Dosing for Moderate to Severe Acute Pain in Adults
The recommended dosing regimen for Journavx is a 100 mg oral loading dose taken on an empty stomach, followed by 50 mg every 12 hours starting 12 hours after the initial dose, with subsequent doses taken with or without food. 1
Standard Dosing Protocol
Initial Dose (Dose 1):
- 100 mg orally taken on an empty stomach
- Must be taken at least 1 hour before or 2 hours after food to avoid delayed onset of action
- Clear liquids are permitted during this fasting period (water, apple juice, vegetable broth, tea, black coffee) 1
Maintenance Doses (Starting 12 hours after initial dose):
- 50 mg orally every 12 hours
- These doses may be taken with or without food
- Continue for the shortest duration consistent with treatment goals
- Use beyond 14 days has not been studied 1
Critical Administration Instructions:
- Swallow tablets whole—do not chew or crush
- Avoid grapefruit-containing foods or beverages throughout treatment 1
Dosing Modifications for Hepatic Impairment
Severe Hepatic Impairment (Child-Pugh Class C):
- Avoid use entirely 1
Moderate Hepatic Impairment (Child-Pugh Class B):
- Dose 1: 100 mg orally on empty stomach (same as standard)
- Doses 2-4: 50 mg every 12 hours (same as standard)
- Dose 5 and beyond: Reduce to 50 mg every 24 hours (once daily instead of twice daily) 1
Mild Hepatic Impairment (Child-Pugh Class A):
- No dose adjustment needed—use standard dosing 1
Dosing with CYP3A Inhibitors
Strong CYP3A Inhibitors:
- Contraindicated—do not use Journavx concurrently 1
Moderate CYP3A Inhibitors:
- Dose 1: 100 mg orally on empty stomach (same as standard)
- Doses 2-4: 50 mg every 12 hours (same as standard)
- Dose 5 and beyond: Reduce to 50 mg every 24 hours 1
- This mirrors the moderate hepatic impairment dosing adjustment
Important: Grapefruit contains moderate CYP3A inhibitors, which is why it must be avoided throughout treatment 1
Clinical Context and Evidence
The dosing regimen is supported by two pivotal Phase 3 trials in abdominoplasty (n=1,118) and bunionectomy (n=1,073) patients, where this regimen demonstrated statistically significant and clinically meaningful pain reduction versus placebo over 48 hours 2. In the abdominoplasty trial, the least squares mean difference in pain intensity was 48.4 points (P<0.0001), and in bunionectomy it was 29.3 points (P=0.0002) 2.
In a Phase 3 single-arm study across diverse surgical and non-surgical acute pain conditions (N=256), 83.2% of patients rated Journavx effectiveness as good, very good, or excellent using this dosing regimen 3. A subsequent Phase 4 study in arthroscopic and laparoscopic procedures showed 90.9% of patients rated pain control favorably, with 76.1% requiring no opioid rescue 4.
Common Pitfalls to Avoid
Food timing with first dose: The loading dose MUST be taken on an empty stomach. Taking it with food delays onset of action, which is critical for acute pain management 1
Overlooking CYP3A interactions: Always screen for strong CYP3A inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) before prescribing—these are absolute contraindications. Moderate inhibitors (erythromycin, diltiazem, verapamil, fluconazole) require dose reduction after the first 4 doses 1
Hepatic function assessment: Patients with moderate hepatic impairment need dose reduction after the first 4 doses. Those with severe hepatic impairment should not receive Journavx at all 1
Duration limits: There are no safety or efficacy data beyond 14 days of use. This is strictly for acute pain management, not chronic pain 1
Tablet integrity: Crushing or chewing tablets alters pharmacokinetics—tablets must be swallowed whole 1
Renal Impairment
No dose adjustment is specified in the FDA labeling for renal impairment, suggesting standard dosing can be used regardless of kidney function 1.